Stroke Clinical Trial
Official title:
An Evaluation of the Safety and Effectiveness of the Conformal CLAAS System for Left Atrial Appendage Occlusion
NCT number | NCT05147792 |
Other study ID # | 21-101 |
Secondary ID | |
Status | Suspended |
Phase | N/A |
First received | |
Last updated | |
Start date | May 26, 2022 |
Est. completion date | August 2030 |
Verified date | May 2024 |
Source | Conformal Medical, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amuletâ„¢ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amuletâ„¢ devices and will be followed for 5 years after device implant.
Status | Suspended |
Enrollment | 1600 |
Est. completion date | August 2030 |
Est. primary completion date | August 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or non-pregnant female aged =18 years 2. Documented non-valvular AF (paroxysmal, persistent, or permanent) 3. High risk of stroke or systemic embolism, defined as CHADS2 score of >2 or CHA2DS2-VASc score of = 3 4. Has an appropriate rationale to seek a non-pharmacologic alternative to long-term oral anticoagulation 5. Deemed by the site investigator to be suitable for short term oral anticoagulation therapy but deemed less favorable for long-term oral anticoagulation therapy. 6. Deemed appropriate for LAA closure by the site investigator and a clinician not a part of the procedural team using a shared decision-making process in accordance with standard of care 7. Able to comply with the protocol-specified medication regimen and follow-up evaluations 8. The patient (or legally authorized representative, where allowed) has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate institutional review board (IRB)/Regional Ethics Board (REB)/Ethics Committee (EC). Exclusion Criteria: 1. Pregnant or nursing patients and those who plan pregnancy in the period up to one year following the index procedure. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to index procedure. 2. Anatomic conditions that would prevent performance of an LAA occlusion procedure (e.g., prior atrial septal defect [ASD] or high-risk patent foramen ovale [PFO], surgical repair or implanted closure device, or obliterated or ligated left atrial appendage) 3. Atrial fibrillation that is defined by a single occurrence or that is transient or reversible (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 4. A medical condition (other than atrial fibrillation) that mandates long-term oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or mechanical heart valve) 5. History of bleeding diathesis or coagulopathy, or patients in whom antiplatelet and/or anticoagulant therapy is contraindicated 6. Documented active systemic infection 7. Symptomatic carotid artery disease (defined as >50% stenosis with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is <50% stenosis noted at the site of prior treatment 8. Recent (within 30 days of index procedure) or planned (within 60 days post-procedure) cardiac or non-cardiac interventional or surgical procedure 9. Recent (within 30 days of index procedure) stroke or transient ischemic attack 10. Recent (within 30 days of index procedure) myocardial infarction 11. Vascular access precluding delivery of implant with catheter-based system 12. Severe heart failure (New York Heart Association Class IV) 13. Prior cardiac transplant, history of mitral valve replacement or transcatheter mitral valve intervention, or any mechanical valve implant 14. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation) 15. Platelet count <75,000 cells/mm3 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3 16. Known allergy, hypersensitivity or contraindication to aspirin, heparin, or device materials (e.g., nickel, titanium) that would preclude any P2Y12 inhibitor therapy, or the patient has contrast sensitivity that cannot be adequately pre-medicated 17. Actively enrolled or plans to enroll in a concurrent clinical study in which the active treatment arm may confound the results of this trial 18. Unable to undergo general anesthesia 19. Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 5 years 20. A condition which precludes adequate transesophageal echocardiographic assessment Echo exclusion criteria: 1. Left atrial appendage anatomy which cannot accommodate a commercially available control device or the CLAAS device per manufacturer IFU (e.g., the anatomy and sizing must be appropriate for both devices to be enrolled in the trial) 2. Intracardiac thrombus or dense spontaneous echo contrast consistent with thrombus, as visualized by TEE prior to implant 3. Left ventricular ejection fraction (LVEF) <30% 4. Moderate or large circumferential pericardial effusion >10 mm or symptomatic pericardial effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade physiology 5. Atrial septal defect that warrants closure 6. High risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (excursion >15 mm or length > 15 mm) or large shunt (early [within 3 beats] and/or substantial passage of bubbles, e.g., >20) 7. Moderate or severe mitral valve stenosis (mitral valve area <1.5 cm2) 8. Complex atheroma with mobile plaque of the descending aorta and/or aortic arch 9. Evidence of cardiac tumor |
Country | Name | City | State |
---|---|---|---|
Georgia | Chapidze | Tbilisi | |
Georgia | Israeli-Georgian Medical Research Clinic Helsicore | Tbilisi | |
Georgia | Tbilisi Heart and Vascular Clinic | Tbilisi | |
United States | Mission Hospital | Asheville | North Carolina |
United States | Emory University | Atlanta | Georgia |
United States | Northside Hospital, Inc | Atlanta | Georgia |
United States | Piedmont Health Institute | Atlanta | Georgia |
United States | Medical Center of Aurora | Aurora | Colorado |
United States | Medstar Union Memorial Hospital | Baltimore | Maryland |
United States | Grandview Medical Center | Birmingham | Alabama |
United States | University of Buffalo / Kaleida Health | Buffalo | New York |
United States | Lahey Hospital & Medical Centeer | Burlington | Massachusetts |
United States | Erlanger Health System | Chattanooga | Tennessee |
United States | Ohio Health Research Institute | Columbus | Ohio |
United States | Ascension St. John's Hospital | Detroit | Michigan |
United States | Corewell Health | Grand Rapids | Michigan |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Cooper University - Heart House | Haddon Heights | New Jersey |
United States | Terrebone - Cardiovascular Institute of the South | Houma | Louisiana |
United States | Memorial Hermann Memorial City Medical Center | Houston | Texas |
United States | Ascension St. Vincent - Carmel, IN | Indianapolis | Indiana |
United States | Ascension St. Vincent's Jacksonville | Jacksonville | Florida |
United States | St. Bernard's Medical Center | Jonesboro | Arkansas |
United States | Saint Luke's Hospital of Kansas City | Kansas City | Missouri |
United States | Tennova Healthcare - Turkey Creek Medical Center | Knoxville | Tennessee |
United States | Largo Medical Center | Largo | Florida |
United States | Catholic Medical Center | Manchester | New Hampshire |
United States | WellStar Kennestone Hospital | Marietta | Georgia |
United States | Baptist Hospital of Miami | Miami | Florida |
United States | West Virginia University | Morgantown | West Virginia |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Mount Sinai Hospital | New York | New York |
United States | Senatra Norfolk | Norfolk | Virginia |
United States | Trident Medical Center | North Charleston | South Carolina |
United States | Kansas City Cardiac Arrhythmia Research, LLC | Overland | Missouri |
United States | Abrazo Arizona Heart Hospital | Phoenix | Arizona |
United States | Lifespan Health System | Providence | Rhode Island |
United States | Chippenham Hospital | Richmond | Virginia |
United States | Carilion Clinic | Roanoke | Virginia |
United States | CentraCare Heart and Vascular Center | Saint Cloud | Minnesota |
United States | Pacific Heart Institute | Santa Monica | California |
United States | HonorHealth | Scottsdale | Arizona |
United States | Ascension Providence Hospital | Southfield | Michigan |
United States | Baystate Medical Center | Springfield | Massachusetts |
United States | USF - Tampa General Hospital | Tampa | Florida |
United States | Pima Heart & Vascular | Tucson | Arizona |
United States | North Mississippi Medical Center | Tupelo | Mississippi |
United States | Community Memorial Hospital Ventura | Ventura | California |
United States | MedStar Washington Hospital Center | Washington | District of Columbia |
United States | Cardiovascular Research Institute of Kansas | Wichita | Kansas |
United States | Lankenau Heart Institute | Wynnewood | Pennsylvania |
Uzbekistan | Republican Specialized Center for Surgery named after V. Vakhidov | Chilanzar | Tashkent |
Uzbekistan | AKFA Medline | Olmazor | Tashkent |
Lead Sponsor | Collaborator |
---|---|
Conformal Medical, Inc |
United States, Uzbekistan, Georgia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Procedure-related complications, all-cause death, major bleeding | The primary safety endpoint is a composite of 1) major procedure-related complications including a) cardiac perforation, b) pericardial effusion requiring drainage, c) ischemic stroke, d) device embolization, and e) major vascular complications, or 2) major bleeding, or 3) all-cause death | 12 months | |
Primary | Ischemic stroke and systemic embolism | The primary effectiveness endpoint is a composite of ischemic stroke and systemic embolism through 18 months. | 18 months | |
Secondary | All Cause Mortality | A secondary safety endpoint is all-cause mortality including cardiovascular through 18 months | 18 months | |
Secondary | Myocardial Infarction | A secondary safety endpoint is myocardial infarction evaluated through 7 days post-procedure | 7 days | |
Secondary | Neurologic Events | A secondary safety endpoint is neurologic events including stroke (ischemic and hemorrhagic) and TIA | 45 days | |
Secondary | Closure Success | A secondary performance and efficacy endpoint is closure success at 12 months based upon each of the following criteria: a) demonstration of peri-device flow =5 mm, and b) demonstration of peri-device flow =3 mm | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Recruiting |
NCT03869138 -
Alternative Therapies for Improving Physical Function in Individuals With Stroke
|
N/A | |
Completed |
NCT04034069 -
Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT04101695 -
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Completed |
NCT00391378 -
Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)
|
N/A | |
Recruiting |
NCT06204744 -
Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial
|
N/A | |
Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
Active, not recruiting |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT03985761 -
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
|
N/A | |
Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
Recruiting |
NCT06034119 -
Effects of Voluntary Adjustments During Walking in Participants Post-stroke
|
N/A | |
Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
Completed |
NCT01662960 -
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
|
N/A | |
Recruiting |
NCT05854485 -
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
|
N/A | |
Active, not recruiting |
NCT05520528 -
Impact of Group Participation on Adults With Aphasia
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Completed |
NCT05805748 -
Serious Game Therapy in Neglect Patients
|
N/A | |
Recruiting |
NCT05993221 -
Deconstructing Post Stroke Hemiparesis
|